Researchers combined MRI and blood markers to identify pancreatic cancer patients at higher risk of early recurrence after surgery. The study, published in Holistic Integrative Oncology in the brief, describes an approach intended to flag recurrence risk before a surgeon makes an incision, using a multimodal model. For clinicians and sponsors, the value is in decision support—helping target adjuvant strategies, clinical trial eligibility, and intensity of follow-up based on a structured risk profile. In a disease where late detection and rapid progression limit outcomes, an earlier stratification step can also accelerate more precise development programs. The immediate industry relevance is methodological: the story underscores a movement toward multimodal recurrence prediction that pairs imaging biomarkers with circulating signals to improve practical discrimination for real-world care pathways.